U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07375225) titled 'Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy' on Jan. 21.
Brief Summary: Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Study Start Date: Dec. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Hypercholesterolaemia
Intervention:
DRUG: Praluent (Alirocumab)
Alirocumab 300 mg injection
Recruitment Status: RECRUITING
Sponsor: Federico II University
Information provided by (Responsible Party): Pasquale Perrone Filardi, Federico II University
Published by HT Digital Content Services with permission from Health...